Development of potent and selective factor Xa inhibitors.
暂无分享,去创建一个
W D Shrader | B. Katz | C. Luong | E. Verner | E. Leahy | P. Sprengeler | P A Sprengeler | B A Katz | K Elrod | C Luong | R Rai | E Verner | W. Shrader | R. Rai | Y. Li | L Cregar | X. Chen | W B Young | A Kolesnikov | Y Li | E Leahy | J Burgess-Henry | J C Sangalang | D Allen | X Chen | K. Elrod | D. Allen | L. Cregar | A. Kolesnikov | W. Young | J. Sangalang | J. Burgess-Henry
[1] B. Zhu,et al. Chapter 9. Factor Xa inhibitors: Recent advances in anticoagulant agents , 2000 .
[2] J. Janc,et al. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site. , 2002, Journal of molecular biology.
[3] W. R. Ewing,et al. PROGRESS IN THE DESIGN OF INHIBITORS OF COAGULATION FACTOR XA , 1999 .
[4] P. Sprengeler,et al. Perspectives on factor Xa inhibition. , 2001, Current medicinal chemistry.
[5] R. Wexler,et al. Chapter 9. Anticoagulants: Thrombin and Factor Xa Inhibitors , 1999 .
[6] W. Moore,et al. Neutrophil myeloperoxidase is a potent and selective inhibitor of mast cell tryptase. , 1999, Archives of biochemistry and biophysics.